Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. Issue 8 (16th November 2016)

• Record Type: Journal Article
• Authors: Schernthaner, Guntram; Lavalle-González, Fernando J.; Davidson, Jaime A.; Jodon, Holly; Vijapurkar, Ujjwala; Qiu, Rong; Canovatchel, William
• Is Part Of: Postgraduate medicine. Volume 128:Issue 8(2016)
• Page Start: 725
• Page End: 730
• Publication Date: 2016-11-16
• Subjects: Canagliflozin -- type 2 diabetes mellitus -- sodium glucose co-transporter 2 (SGLT2) inhibitor -- antihyperglycemic agent -- body weight; Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Periodicals; 610.5
• DOI: 10.1080/00325481.2016.1210988
• Languages: English
• ISSNs: 0032-5481

Abstract

ABSTRACT: Objectives : To evaluate the proportion of patients with type 2 diabetes mellitus (T2DM) achieving reductions in both glycated hemoglobin (HbA1c) and body weight with canagliflozin, a sodium glucose co-transporter 2 inhibitor, versus sitagliptin over 52 weeks. Methods : Data were pooled from two, randomized, Phase 3 studies of canagliflozin 100 and 300 mg versus sitagliptin 100 mg as add-on to metformin, and canagliflozin 300 mg versus sitagliptin 100 mg as add-on to metformin plus sulfonylurea (N = 1856). The composite end points of change from baseline in both HbA1c <0% and body weight <0 kg, and attainment of HbA1c <7.0% and body weight reduction ≥5% at Week 52 were evaluated. Safety was assessed based on adverse event reports. Results : Canagliflozin provided reductions in HbA1c and body weight over 52 weeks versus sitagliptin. A greater proportion of patients had both HbA1c and body weight reductions with canagliflozin 100 and 300 mg versus sitagliptin 100 mg (67.7%, 72.6%, and 44.1%, respectively). Among patients with HbA1c and body weight reductions, more patients achieved the composite end point of HbA1c <7.0% and body weight reduction ≥5% with canagliflozin 100 and 300 mg versus sitagliptin 100 mg (18.9%, 18.3%, and 5.7%, respectively). Canagliflozin was generally well tolerated. Conclusions : A greater proportion of patients with T2DM achieved reductions in both HbA1c and body weight, and more patients with HbA1c and body weight reductions achieved HbA1c <7.0% and body weight reduction ≥5% with canagliflozin versus sitagliptin over 52 weeks. Clinical trial registration :www.ClinicalTrials.gov identifiers are NCT01106677; NCT01137812.